Activity

Eric,

Thank you for your follow-up–and ideas.

Regarding AlohaHealth, I would definitely be willing to sign-up; and see what they have to say; as I’m definitely interested in pursuing some Clinical Trials following my adjuvant chemo–i.e.; I want to continue doing what I can even beyond the traditional treatment cycle to continue to battle this. Bottom line–Please make the introduction to Aloha for me; and I’ll work with them to use their AI technology to assist. Thank you.

Regarding CancerCommons, I will register with them; and go through their process to see what they may come up with; and will be happy to ask them to copy you for any thoughts/comments.

Regarding this new FDA approved process, I’m extremely intrigued by this. Fortunately, I have recently had a successful R0 resection; and hence, my main concern at this time is micro-metastasis where a tumor could re-emerge some time later; and hence, my question to you about this procedure is does it work with micro-metastasis, or is it only for Stage IV established tumors? Put another way, if it would work for “any” possible cancer, then I definitely want to look into this further.

Finally, I made reference to doing two “tumor analyses” in my original description of my situation–i.e.; both the Prethera KnowYourTumor and the SEngine PARIS Tests; and I’ve since received the completed reports of both of them. Interestingly, both of those reports found that my tumor seemed to react to Gemcitabine; and in fact, the Organoid study said that my tumor had “no reaction” to the elements of Folfirinox (they test the elements individually versus in combination)–which is strange. More specifically, the SEngine PARIS test showed that my sample had “no reaction” to the Folfirinox elements; however, I had used Folfirinox for neoadjuvant therapy with decent results—e.g.; tumor shrank ~40% before surgery, and my C19-9 markers decreased steadily from 230 to 156. So, it’s “interesting” that the test showed “no reaction”. Put another way, that seems like a reaction to me, so I’m confused. Again, I’m ready to start my adjuvant chemotherapy following my successful R0 resection; and the current plan is to go with mFolfirinox. Following on this further, my sample showed a response to Gemcitabine—which is great/encouraging—however, any/all the studies you see highlight that Folfirinox shows much better long-term survival rates over Gemcitabine; and hence, it begs the question what should I do with my adjuvant chemo—i.e.; Folfirinox shows better efficacy in most all studies, but my sample shows Gemcitabine potentially having better impact. So, put another way, it seems like a potential quandry—i.e.; go with what is “preferred” showing longer-term survival, or go with what my tumor seems to “react” better to.

As always, any thoughts/comments/guidance would be appreciated. Thank you.